NCT04872023View on ClinicalTrials.gov

Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

June 13, 2022

Study Completion Date

January 27, 2023

Conditions
Multiple Myeloma
Interventions
OTHER

Blood and bone marrow sampling

Blood and bone marrow sampling

Trial Locations (1)

Unknown

CHU Rennes, Rennes

All Listed Sponsors
lead

Rennes University Hospital

OTHER

NCT04872023 - Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression | Biotech Hunter | Biotech Hunter